Physician profile

Patricia A Oconnell

Acute Care (Nurse Practitioner) · Pasadena, CA

NPI 1770877409

$1,515.47

in general payments reported to CMS, 2019-2025

8 companies · none reported in 2025

See the full distribution for Acute Care (Nurse Practitioner)

Payments by year

General payments by program year, as reported to CMS.

What the payments were for

Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.

View as a table
Payment typeAmount (2023-2025)
Food and Beverage$276.48
Travel and Lodging$4.90

Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.

Who reported paying

General payments only, as reported to CMS. Product names cover 2023-2025.

CompanyGeneral paymentsYearsTop products
Novo Nordisk INC $502.93 2021-2022
Lilly USA, LLC $287.66 2021-2023 Mounjaro
Abbott Laboratories $204.87 2021
Insulet Corporation $177.72 2021-2022
Bayer Healthcare Pharmaceuticals INC. $151.48 2023
Boehringer Ingelheim Pharmaceuticals, INC. $146.33 2021
Amgen INC. $22.26 2021
Medtronic, INC. $22.22 2022

Drugs and devices associated with these payments

CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.

If you want to bring it up

Most clinicians are glad to talk about this. A respectful way in:

These are normal questions. A good clinician will welcome them.

Share this page

Payment summary

Patricia A Oconnell

$1,515.47

in general payments reported 2019-2025

Years
2021-2023
Top company
Novo Nordisk INC

https://glasscript.com/doctor/10646578/patricia-a-oconnell

Source: CMS Open Payments, program years 2019-2025. Payments are legal and often routine.

Keep an eye on this page

Get an email when the next June refresh changes this page. No account needed.

Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.